Gyongyi Szabo, MD, PhD, FAASLD

Biography

Gyongyi Szabo, MD, PhD, FAASLD, AGAF, FACP


Gyongyi Szabo, MD, PhD is and the Mitchell T. Rabkin, M.D. Chair, Professor of Medicine and Faculty Dean at Harvard Medical School and Chief Academic Officer at the Beth Israel Deaconess Medical Center and Beth Israel Lahey Health.

A physician scientist gastroenterologist and an internationally known expert in liver diseases, Dr. Szabo investigates the complex role of chronic inflammation in progression of liver diseases and focuses on molecular pathways to identify potential new therapeutic targets. Her investigations revealed the importance of micro-RNAs and extracellular vesicles in inter-cellular and inter-organ communication in liver diseases. Dr. Szabo's group discovered that NLRP3 inflammasome activation and the IL-1ß pathway are potential therapeutic targets in alcohol-associated hepatitis and MASLD leading to first-time clinical trials in alcohol-associated hepatitis with IL-1 inhibition. Dr. Szabo conducted over 40 clinical trials in liver diseases and she serves on scientific advisory boards of numerous pharmaceutical industry partners. She is elected member of the Hungarian Academy of Sciences and fellow of the AASLD, AGA and the American College of Physicians (ACP). Dr. Szabo has chaired the NIAAA Board of Advisors and was member of the AASLD Governing Board and President in 2015. She became the inaugural Editor-in-Chief of Hepatology Communications and received the 2020 Distinguished Scientific Achievement Award from the American Liver Foundation.